Note: This article does not constitute any investment advice and recommendations, subject to official/company announcements; This article is only an introduction to medical and health-related drugs, and non-treatment options (if involved) are recommended and do not represent the position of
Any reproduction of articles requires permission
The agreement includes an upfront payment totaling up to $21.
5 million and target nomination fees for up to six targets, additional R&D and commercial milestone payments, and phased royalties ranging from medium to low double digits
Insilico, a clinical-stage drug discovery company powered by artificial intelligence (AI), announced a multi-year strategic research collaboration
with Sanofi for multiple targets.
Under the terms of the agreement, the collaboration will leverage Insilico's AI-driven Pharma.
AI drug discovery platform to advance drug candidate development based on no more than six innovative targets
Changchun Xiao, Head of Research at Sanofi China, said: "Insilico is one of the recognized leaders in AI drug discovery and we look forward to working
The collaboration will complement each other's capabilities and synergies and will facilitate drug discovery at
Sanofi China Research Institute (SIBR).
Under the terms of the agreement, Sanofi will pay Insilico's aggregate upfront payment and target nomination fees of up to US$21.
5 million, supported by Insilico's end-to-end AI drug discovery platform Pharma.
AI and a team of interdisciplinary drug discovery scientists to identify, synthesize and advance research on high-quality lead compounds to clinical development
If the collaboration reaches key R&D and commercial milestones, Insilico will also receive additional milestone payments, totaling up to $1.
The partnership will also provide phased royalties
ranging from medium to low double digits for the commercialization of successfully developed products.
Alex Zhavoronkov, Founder and CEO of Insilico, said, "Sanofi has a clear strategy in AI-driven drug discovery and we are very pleased to partner
This close collaboration will not only enrich Sanofi's drug pipeline, but also complement the capabilities
of a leading AI startup.
Ren Feng, Co-CEO and Chief Scientific Officer of Insilico, said, "We are excited to enter into this partnership with Sanofi, and we believe that the combination of Sanofi's excellent drug discovery capabilities and Insilico's powerful artificial intelligence platform will accelerate the development of innovative therapeutics to meet unmet medical needs
as quickly as possible.
" It is expected that the two parties will jointly use cutting-edge artificial intelligence technology to make major breakthroughs
in drug research and development.
About InsilicoAbout Insilico
Insilico is an end-to-end artificial intelligence (AI)-driven drug discovery company that connects biological, chemical and clinical trial analysis through next-generation AI systems, leveraging modern machine learning technologies such as deep generative models, reinforcement learning, and transformation models to build a powerful and efficient AI drug discovery platform to identify novel targets and generate drug candidates with specific attribute molecular structures
Insilico focuses on areas of unmet medical need such as cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases, and promotes and accelerates the development of
For more information, visit the website: www.